Merriman Curhan initiates coverage on Salix Pharmaceutical (Nasdaq: SLXP) with a Buy.
Merriman analyst says, "We believe Salix represents a unique play within the specialty pharmaceutical space. The company continues to expand its array of gastrointestinal therapeutic programs. Additionally, Salix has been aggressive at expanding label indications for approved products into areas of unmet medical need. We believe a specialty focused sales force such as the one Salix commands allows the company to attain faster and greater market penetration, thereby growing the top-line at a much faster pace. This is a unique differentiator in the spec pharma arena, in our view."
No comments:
Post a Comment